Organogenesis price to free cash flow ORGO

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Oct 23, 2026: 6.1×
5-year median: 44.4×
Against its 5-year history: 0th; percentile: 0 is its lowest day, 100 its highest
5-year range: 6.1× to 189×
Peer median: 11.4×

Organogenesis' price to free cash flow is 6.1× as of Oct 23, 2026.

That is below its 5-year median of 44.4×, lower than on 100% of days in the last 5 years.

Over that time it ranged from 6.1× in Oct 2026 to 189× in Feb 2025.

The median for 10 large drugmakers of a similar size is 11.4×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.1×	6.1×	20.0×
2025	160×	103×	189×
2024	109×	38.4×	138×
2023	47.9×	47.9×	56.1×
2022	53.9×	18.2×	57.7×
2021	33.6×	33.6×	84.1×

Against its peers

Companies in Drug Manufacturers - General nearest Organogenesis' size, closest first, today.

Company	Price to free cash flow
ORGOOrganogenesis	6.1×
NATRNatures Sunshine Products	11.8×
LFVNLifevantage	11.0×
SPROSpero Therapeutics	n/m
ATNMActinium Pharmaceuticals	n/m
ARVNArvinas	n/m
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
Peer median	11.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Organogenesis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.